Xeris Biopharma (XERS) confirms board and executive leadership adjustments in its latest regulatory filing, signaling standard corporate governance updates for the US-based firm.
8-K filing reports departure of directors and appointment of officers with compensatory arrangements, indicating routine corporate governance changes.
Xeris Biopharma Holdings, Inc. disclosed routine corporate governance updates in a recent 8-K filing. The report details the departure of specific directors alongside the appointment of new officers and associated compensatory arrangements.
The filing covers Item 5.02, which pertains to the departure of directors, the election of new directors, the appointment of officers, and the establishment of compensatory arrangements for those officers.